Merci pour toutes ces belles années sur notre plateforme, nous vous informons que nous avons pris la décision de transférer notre activité sur notre page Facebook. https://www.facebook.com/congresmedical/
A revision of the Clinical Trials Regulation has been adopted by European legislation makers. This revised framework will bring significant advances compared to todays’ situation. However, the original objectives of this legislation should be remembered: these were to enhance efficiency of the overall clinical trials authorization process and, in turn, to boost the EU’s competitiveness as a place to conduct research and make for more efficient patients access to new innovative treatments.
Especially the procedure for assessment and approval of multinational clinical trial authorisation applications will change: in future, each Member State will have to generate one single opinion and the competent authority of the “reporting Member State” will coordinate the assessment process until a common decision is reached. Ethics committees are supposed to be an essential part of this assessment process but it is left to the Member State to decide how this will be achieved.
Today, we are at a critical stage in the process where the new rules have to be integrated into the national systems in each Member State. When establishing procedures at national level, it is now essential that Ethics Committees find ways to ensure both a reliable independent ethical review delivered within the defined time frame as well as the relevant level of collaboration during the process with the national competent authority. This will require a re-thinking of ethical review processes and Ethics Committee infrastructure in most Member States. Early discussion with Ethics Committee members and competent authorities from other countries and with concerned stakeholders could help to define the optimal solutions and support the development of a streamlined and a more harmonised system for the European Union.
EFGCP Square de Meeûs - Rue de l'Industrie 4 1000 Bruxelles BELGIUM
Congrès, formations ou conférences médicales REF #28-5582 EFGCP Multi-Stakeholder Workshop & Discussion on 'How to Ensure Optimal Ethical Review within the New Clinical Trials Regulation?' Publié sur congres-medical.com le : 2014-06-25 14:46:19 Congrès, formations ou conférences médicales en _AUTRES